Treatment of chemotherapy-associated cardiomyopathy
| Autor: | Amanda W Cai, Bhavadharini Ramu, Marian H Taylor |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Heart Diseases medicine.medical_treatment Population Cardiomyopathy MEDLINE Antineoplastic Agents 030204 cardiovascular system & hematology Asymptomatic 03 medical and health sciences 0302 clinical medicine Neoplasms medicine Humans 030212 general & internal medicine Intensive care medicine education Cardiotoxicity Chemotherapy education.field_of_study business.industry Cancer medicine.disease Heart failure medicine.symptom Cardiology and Cardiovascular Medicine business Cardiomyopathies |
| Zdroj: | Current opinion in cardiology. 34(3) |
| ISSN: | 1531-7080 |
| Popis: | Purpose of review The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival. Recent findings Recent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD. However, this is largely based on data extrapolated from the general heart failure population (including patients without cancers) and is not based on strong evidence. There is now emerging evidence for the prevention and treatment of heart failure related to certain established chemotherapeutic drugs, whereas there is lack of trials for specific cardioprotective strategies to reduce cardiotoxicity of newer targeted cancer therapies. Summary In this article, we discuss the most recent literature for the management of asymptomatic left ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use of goal-directed medical therapies as well as discuss the role for advanced heart failure treatment in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|